Literature DB >> 9933147

Signaling via A2A adenosine receptor in four PC12 cell clones.

G Arslan1, B Kull, B B Fredholm.   

Abstract

PC12 cells are genetically labile and so-called wild-type cells comprise multiple subclones. We have examined the A2A adenosine receptor signal transduction pathways in four such clones (denoted clones 1, 19, 21 and 27) of PC12 cells. Adenosine A2A, A2B and A1 receptor mRNAs were detected in all four clones by RT-PCR, whereas no A3 receptor mRNA was found. A2A receptors were quantitated by radioligand binding using the antagonist radioligand [3H]SCH 58261 ([3H]-5-amino-7(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4 triazolo [1,5-c] pyrimidine). The Bmax was highest in clone 1 followed by clones 21, 19 and 27. Whereas the amount of G(i) protein appeared similar in all four clones, the amount of G(s) protein was higher in clones 21 and 27 than in the other two clones. Maximal responses to the non-selective adenosine analogue NECA (5'-N-ethylcarboxamidoadenosine) were similar to those observed with the selective adenosine A2A receptor agonist CGS 21680 (2-[p-(2-carbonylethyl) phenylethylamino]-5'-N-ethylcarboxamidoadenosine), and were approximately equal in clones I and 21, but lower in clone 19 and very low in clone 27. For both compounds EC50 was significantly higher in clone 27 than in clone 1. In both clones the response to NECA could be competitively antagonized by a selective adenosine A2A antagonist, SCH 58261. The present results show that different clones of PC 12 cells differ widely in the cAMP increase induced by adenosine analogues and that this is due to differences in the amount of adenosine A2A receptor, G protein and effector. A large difference in receptor number resulted in differences in potency of an agonist.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933147     DOI: 10.1007/pl00005319

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.

Authors:  S Merighi; K Varani; S Gessi; E Cattabriga; V Iannotta; C Ulouglu; E Leung; P A Borea
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

3.  How adenylate cyclase choreographs the pas de deux of the receptors heteromerization dance.

Authors:  A S Woods; S N Jackson
Journal:  Neuroscience       Date:  2013-02-19       Impact factor: 3.590

4.  Formation of a ternary complex among NHERF1, beta-arrestin, and parathyroid hormone receptor.

Authors:  Christoph Klenk; Thorsten Vetter; Alexander Zürn; Jean-Pierre Vilardaga; Peter A Friedman; Bin Wang; Martin J Lohse
Journal:  J Biol Chem       Date:  2010-07-23       Impact factor: 5.157

5.  The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions.

Authors:  P Svenningsson; G G Nomikos; B B Fredholm
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

6.  Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum.

Authors:  Anthony H Stonehouse; Frederick S Jones
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

7.  Vital role of protein kinase C-related kinase in the formation and stability of neurites during hypoxia.

Authors:  Bettina Thauerer; Stephanie zur Nedden; Gabriele Baier-Bitterlich
Journal:  J Neurochem       Date:  2010-01-28       Impact factor: 5.372

8.  Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine.

Authors:  Jiang-Ning Yang; Olga Björklund; Karin Lindström-Törnqvist; Eva Lindgren; Therese M Eriksson; Johan Kahlström; Jiang-Fan Chen; Michael A Schwarzschild; Irene Tobler; Bertil B Fredholm
Journal:  J Appl Physiol (1985)       Date:  2008-11-26

9.  Inhibition of the equilibrative nucleoside transporter 1 and activation of A2A adenosine receptors by 8-(4-chlorophenylthio)-modified cAMP analogs and their hydrolytic products.

Authors:  Oliver Waidmann; Thomas Pleli; Karel Dvorak; Christina Baehr; Ulrich Mondorf; Guido Plotz; Ricardo M Biondi; Stefan Zeuzem; Albrecht Piiper
Journal:  J Biol Chem       Date:  2009-09-29       Impact factor: 5.157

10.  HIF-1 alpha is an essential effector for purine nucleoside-mediated neuroprotection against hypoxia in PC12 cells and primary cerebellar granule neurons.

Authors:  Stephanie zur Nedden; Bettina Tomaselli; Gabriele Baier-Bitterlich
Journal:  J Neurochem       Date:  2008-02-04       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.